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Abstract
Background The etiological role of human papillomavirus (HPV) in oropharyngeal squamous cell carcinoma (OPSCC) is 
confirmed. However, the role of other oncoviruses in OPSCC is unknown.
Materials and methods A total of 158 consecutive OPSCC patients treated with curative intent were included. DNA extracted 
from tumor sections was used to detect Epstein–Barr virus (EBV), HPV, and the following polyomaviruses: John Cun-
ningham virus (JCV), Simian virus 40 (SV40), and BK virus (BKV) with PCR. In addition, p16 expression was studied by 
immunohistochemistry, and EBV-encoded small RNA (EBER) transcripts were localized by in situ hybridization. The effect 
of viral status on overall survival (OS) and disease-free survival (DFS) was analyzed.
Results A total of 94/158 samples (59.5%) were HPV-positive, 29.1% contained BKV DNA, 20.3% EBV DNA, 13.9% JCV 
DNA, and 0.6% SV40 DNA. EBER was expressed only in stromal lymphocytes adjacent to the tumor and correlated with 
HPV positivity (p = 0.026). p16 expression associated only with HPV. None of the three polyomaviruses had an impact on 
survival. Patients with EBER-positive but HPV-negative OPSCC had significantly poorer OS and DFS than those with HPV-
positive OPSCC and slightly worse prognosis compared with the patients with EBER-negative and HPV-negative OPSCC.
Conclusion Polyomaviruses are detectable in OPSCC but seem to have no impact on survival, whereas HPV was the strong-
est viral prognostic factor. EBER expression, as a sign of latent EBV infection, may have prognostic impact among patients 
with HPV-negative OPSCC. EBER analysis may identify a new subgroup of OPSCCs unrelated to HPV.
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NPC  Nasopharyngeal carcinoma
OPSCC  Oropharyngeal squamous cell carcinoma
OS  Overall survival
qPCR  Quantitative polymerase chain reaction
SV40  Simian virus 40
Introduction
Several viruses have been detected in head and neck squa-
mous cell carcinoma (HNSCC) [1–7]. Their etiologic and 
prognostic role is of great interest in cancer prevention and 
new management practices including immunotherapy [8–10] 
and treatment de-escalation [11–13].
The incidence of oropharyngeal squamous cell carcinoma 
(OPSCC) is increasing and has been attributed to human 
papillomavirus (HPV) infection. Currently, more than half of 
OPSCCs are HPV-related in many western countries, includ-
ing Finland [14–17]. The prognosis of HPV-related OPSCC 
is more favorable than those of HPV-negative tumors [2, 
15, 18, 19]. In contrast to HPV, the role of other oncogenic 
viruses in OPSCC is poorly understood. Depending on the 
endemic area, Epstein–Barr virus (EBV) is highly related to 
the development of nasopharyngeal carcinoma (NPC) [1, 20, 
21]. EBV-associated carcinomas exhibit a non-replicating 
latent infection, in which translation is limited to particular 
genes. The gene products from latent infections, such as EBV-
encoded RNAs (EBERs), are oncogenic. Importantly, patients 
with EBV-related NPC have a more favorable prognosis than 
those with EBV-negative NPC [1, 22]. Furthermore, HPV has 
recently been found to have a prognostic impact on NPC even 
in non-endemic regions [1] and co-infections with EBV and 
HPV have also been reported [1, 4, 22]. In OPSCC, only a few 
studies have detected EBV [4, 23, 24]. However, sample sizes 
were small in these studies. Accordingly, the prognostic role 
of EBV has remained unclear.
Polyomaviruses have been detected in various cancers [3, 
7, 23, 25, 26]. The etiological role of Merkel cell polyoma-
virus in Merkel cell carcinoma is well-established [25], and 
various polyomaviruses have also been found in HNSCC 
[3, 26]. Polyomaviruses may work as cofactors in malignant 
transformation and tumor progression [3, 27]. Polyomaviruses 
BK virus (BKV) and John Cunningham virus (JCV) have 
been detected in the lip and laryngeal carcinoma, respectively 
[3]. In addition, BKV and JCV have been found in OPSCC 
but their impact on the outcome of OPSCC is unknown. In 
addition, the number of patients was small in these studies [3, 
23, 24]. Polyomavirus Simian virus 40 (SV40) is related to 
malignancies such as osteosarcoma, non-Hodgkin lymphoma, 
and mesothelioma [7, 27, 28]. Additionally, SV40 has been 
detected in HNSCC [3] but its role is unknown.
The most recent (8th) edition of TNM classification [29, 
30] uses p16 immunohistochemistry (IHC) to dichotomize 
OPSCC into HPV-related and -unrelated subgroups. How-
ever, it is widely known that p16 overexpression is highly 
sensitive but only moderately specific in HPV detection, 
as approximately 10% to 20% of p16 positive tumors are 
negative for high-risk HPV DNA [11, 31, 32]. Other onco-
genic viruses can also lead to p16 overexpression in the 
absence of HPV [33]. Silencing of the p16 gene has been, 
however, also observed as a sequela of infection with onco-
genic viruses other than HPV [34]. Thus, it is essential to 
elucidate the causative role of other viruses in OPSCC and 
their possible impact on p16 expression, particularly when 
considering treatment de-escalation for patients without con-
ventional risk factors and suspected to have a tumor with 
viral etiology.
We investigated the presence of HPV and other oncoviruses 
including EBV and polyomaviruses (JCV, BKV, and SV40) 
and their association with clinicopathological variables in an 
OPSCC patient series. The latency of EBV infection was veri-
fied with EBER RNA expression detection. In particular, we 
focused on simultaneous infections with HPV and other onco-
viruses. Moreover, we studied the association of these viruses 
with p16 overexpression and their impact on patient survival.
Materials and methods
Patient cohort
We identified a total of 224 consecutive OPSCC patients 
without previous HNSCC diagnosed between February 2012 
and March 2016 at the Helsinki University Hospital, Hel-
sinki, Finland. Patients with no available tumor tissue for 
p16 and viral status determination (n = 33) were excluded. 
Patients with another primary cancer at the time of OPSCC 
diagnosis were excluded (n = 4). Additionally, patients 
treated with palliative intent were excluded (n = 29). A total 
of 158 patients were treated with curative intent and met the 
inclusion criteria.
Clinical data were collected from hospital registries. 
Clinical- and tumor-related parameters have been discussed 
in part previously [14, 18, 35]. Tumor stage was determined 
according to the  8th edition of the American Joint Committee 
on Cancer staging [29, 30]. Patients received either definitive 
radiotherapy with or without cisplatin-based chemotherapy 
or surgery with or without radiotherapy/chemoradiotherapy 
as primary treatment modalities. The follow-up schedule was 
the same as in our previous report [18].
DNA extraction
DNA was extracted from tumor tissue slides by salting out 
the cellular proteins as described previously [3, 36]. The 
cell nuclei were treated in lysis buffer (10 mM Tris–HCl, 
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400 mM NaCl and 2 mM EDTA, pH 8.2) overnight. Proteins 
were digested by protease K overnight at 37 °C and then 
treated with saturated NaCl followed by centrifugation. Eth-
anol was added to the precipitated protein pellet, and DNA 
was extracted into a microcentrifuge tube for quantification.
HPV genotyping, p16 immunohistochemistry, 
and HPV status
HPV DNA genotyping from tumor tissue slides was per-
formed by nested PCR as described previously [14]. 
MY09/MY11 and GP05 +/bioGP06 + were used as exter-
nal and internal primers, respectively. The genotyping was 
performed with a Multiplex HPV Genotyping  Kit® (Dia-
Mex GmbH, Germany) that detects 24 low-risk (LR) and 
high-risk (HR) HPV genotypes as follows: LR-HPV6, 11, 
42, 43, 44, and 70; and HR-HPV16, 18, 26, 31, 33, 35, 39, 
45, 51, 52, 53, 56, 58, 59, 66, 68, 73, and 82. HPV DNA was 
determined as positive in a tumor sample if DNA positivity 
for any of the HR-HPV genotypes was detected.
p16-INK4a status was determined by IHC on paraffin-
embedded formalin-fixed tissue samples as described earlier 
[14]. Gingival tissue was used as a positive control, and a 
tissue slide in diluent without primary antibody was used as 
a negative control. p16 expression was defined as positive 
if > 70% of the tumor cells had positive immunostaining. A 
composite variable including both p16 status and HR-HPV 
DNA PCR status was used to determine HPV status, as sug-
gested by Smeets et al. [32]. Tumors both HR-HPV DNA 
positive and p16 positive were determined as HPV positive 
(HPV+) and the remaining combinations were assessed as 
HPV negative (HPV−).
Detection of EBV
An in-house PCR and Luminex xMAP-based methods were 
used for EBV DNA detection as described in the previous 
studies [4, 37]. Additionally, Epstein–Barr virus (EBV)-
encoded small RNA (EBER) transcripts were examined by 
in situ hybridization (ISH) in tumor samples to ensure the 
latency of EBV. Due to tumor tissue unavailability, EBER 
ISH was available in 89.9% (142/158) of tumor samples. 
EBER PNA Probe/Fluorescein and PNA-ISH Detection 
Kit (Dako, Glostrup, Denmark) were used for detecting 
EBV RNA transcripts EBER1 and EBER2 from the TMA 
slides. The methodology has been described in more detail 
in a previous study [4]. The substrate was first incubated 
then treated with eosin and finally mounted in Aquamount 
(Dako). Tumor and stromal cells were evaluated and scored 
separately from TMA slides by two researchers (Reija Ran-
dén-Brady and Jaana Hagström). Inconclusive cases were 
rescored. A total of six punches of each tumor were scored; 
scoring results of EBER in TMA slides were defined as 
follows: negative (−), mild positivity (+), moderate posi-
tivity (++), and strong positivity (+++).
Detection of polyomaviruses
Quantitative PCR (qPCR) (Roche, Light Cycler 96, (Roche 
Diagnostics, Roche Molecular Diagnostics, Pleasanton, 
CA, UA) was used for detecting DNA of the three poly-
omaviruses SV40, JCV, and BKV. The primers used for 
amplification of all three polyomavirus T antigens and the 
methodology of qPCR have been described in the previ-
ous studies [3, 38]. The linear standard curves for JCV and 
BKV were obtained with a serial dilution of plasmids rang-
ing from 1.2 × 100 to 1.2 × 10−2 ng/μl for JCV and 9.5* × 100 
to 9.5 × 10−3 ng/μl for BKV as described earlier [3].
Statistical analysis
The data were analyzed with SPSS 25 (IBM SPSS Statis-
tics 25, IBM, Somers, IL, USA). Categorical variables were 
cross-tabulated using Chi square test with asymptotic and 
exact p values when best suitable. Overall survival (OS) 
and disease-free survival (DFS) were assessed as survival 
endpoints. OS was defined as the time from treatment 
completion to death from any cause. DFS was defined as 
the time from treatment completion to first recurrence or 
death from any cause. Survival curves were drawn using the 
Kaplan–Meier estimate, and the log-rank test was used to 
analyze the statistical significance between subgroups. The 
independent samples t test was performed for comparison of 
means of dichotomized variables. A two-sided p value < 0.05 
was considered statistically significant.
Results
The presence of HPV, EBV, and polyomaviruses 
in tumor samples
Table 1 summarizes the prevalence of five different viral 
DNAs in OPSCC samples. The data on HPV have been pre-
viously published in part in a smaller patient cohort [14]. 
Among the viruses studied, HPV was the most prevalent, 
and HR-HPV DNA was detected in 97 (61.4%) tumor sam-
ples. HPV16 was the most predominant genotype detected 
and was in 90 (92.8%) of the HR-HPV-positive tumors, fol-
lowed by four (4.1%) tumors with HPV33 and three (3.1%) 
with HPV18 genotypes. p16 immunopositivity was detected 
in 117 (74.1%) tumors. Ninety-four (59.5%) tumors were 
both p16- and HPV DNA-positive and were considered as 
HPV positive (HPV +). The remaining 64 (40.5%) tumors 
were considered as HPV negative. EBV DNA was detected 
in 32 (20.3%) tumor samples. JCV DNA was present in 
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22 (13.9%) and BKV DNA in 46 (29.1%) tumor samples. 
SV40 DNA was present only in one (0.6%) tumor sam-
ple. The viral loads of JCV in all samples were low (4.54 
mean copies/100 ng DNA, SD ± 1.95), varying from 2.63 to 
10.47. Higher copy numbers were detected for BKV (mean 
copies 19.21/100 ng DNA, median 4.22/100 ng DNA). 
However, the copy numbers varied widely from 2.09/100 ng 
DNA to 258.00/100 ng DNA.
Expression of EBER in tumor samples
We detected EBER expression in the stromal inflamma-
tory cells adjacent to the tumor invasive front in 43 (30.3%) 
tumor samples. EBER expression was not detectable in 
tumor cells (Fig. 1). EBV DNA positivity was found in 
tumor samples, and EBER expression detected only in the 
inflammatory cells correlated significantly with each other 
(p = 0.041). Among EBV DNA-positive tumor samples, half 
of the samples showed EBER expression (mild high); the 
other half was EBER negative (13/26). Among EBV-neg-
ative tumor samples, most of the samples were also EBER 
negative (74.1%), while 30 (25.9%) samples showed EBER 
expression.
Simultaneous presence of HPV and other 
oncogenic viruses and their correlation with p16 
overexpression in tumor samples
Coinfection with HPV was characteristic for tumors positive 
for other oncogenic viruses; the majority of all EBV DNA-
positive (75.0%), JCV DNA-positive (68.2%), and BKV 
DNA-positive (58.7%) tumors were also HPV DNA- and 
p16-positive (Table 1). The presence of EBV DNA and 
EBER expression was significantly associated with HPV 
status.
Among the 23 p16-positive but HPV DNA-negative 
tumor samples, we found other viruses in nine samples. We 
observed EBV DNA in three tumor samples, JCV in three, 
and BKV in seven samples. Two of these tumors showed 
positivity for both EBV and BKV DNA and two for JCV 
and BKV DNA. Among the three HPV DNA-positive but 
p16-negative samples, only one sample had positivity for 
another oncogenic virus (BKV). Among the 38 HPV and 
p16-negative tumor samples, 18 tumor samples harbored 
DNA from other oncogenic viruses; we observed EBV DNA 
in five tumor samples, JCV DNA in four, BKV in 11, and 
SV40 in one. Two tumors showed positivity for both EBV 
and BKV DNA and one tumor for JCV and BKV DNA. p16 
status did not have a significant association with oncogenic 
viruses except for HPV (Table 1).
Only HPV status classifies OPSCC into two different 
entities
As reported earlier, patients with HPV-positive tumors were 
significantly more often male, non-smokers, and diagnosed 
with disease extended to local lymph nodes compared with 
HPV-negative tumors [14]. In addition, patients with HPV-
negative tumors were significantly more often heavy alcohol 
users and had a higher stage (III–IV) compared with patients 
with HPV-positive tumors. Part of the clinicopathological 
results according to patients with HPV-positive and HPV-
negative tumors has been presented previously in a smaller 
patient cohort [14]. Patients with EBV DNA-positive tumors 
Table 1  Relation of p16 and HPV DNA PCR status to different viruses
p = p value
p values < 0.05 are bolded
*Statistical significance of comparison between HPV DNA +/p16 + group and other combinations of HPV DNA and p16
p16+ p16− p HPV+ HPV− p*
HPV DNA+/p16+ HPV DNA−/p16+ HPV DNA+/p16− HPV DNA−/p16−
HPV DNA+ 94 (96.9) 3 (3.1) < 0.001
HPV DNA− 23 (37.7) 38 (62.3)
EBV DNA+ 27 (84.4) 5 (15.6) 0.136 24 (75.0) 3 (9.4) 0 (0.0) 5 (15.6) 0.045
EBV DNA− 90 (71.4) 36 (28.6) 70 (55.6) 20 (15.9) 3 (2.4) 33 (26.2)
EBER+ 36 (83.7) 7 (16.3) 0.080 32 (74.4) 4 (9.3) 0 (0.0) 7 (16.3) 0.026
EBER− 69 (69.7) 30 (30.3) 54 (54.5) 15 (15.2) 3 (3.0) 27 (27.3)
JCV DNA+ 18 (81.8) 4 (18.2) 0.370 15 (68.2) 3 (13.6) 0 (0.0) 4 (18.2) 0.371
JCV DNA− 99 (72.8) 37 (27.2) 79 (58.1) 20 (14.7) 3 (2.2) 34 (25.0)
BKV DNA+ 34 (73.9) 12 (26.1) 0.980 27 (58.7) 7 (15.2) 1 (2.2) 11 (23.9) 0.896
BKV DNA− 83 (74.1) 29 (25.9) 67 (59.8) 16 (14.3) 2 (1.8) 27 (24.1)
SV40 DNA+ 0 (0.0) 1 (100.0) 0.259 0 (0.0) 0 (0.0) 0 (0.0) 1 (100.0) 0.405
SV40 DNA− 117 (74.5) 40 (25.5) 94 (59.9) 23 (14.6) 3 (1.9) 37 (23.6)
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had significantly more often stage I–II disease compared 
with those with EBV DNA-negative tumors. EBER-positive 
tumors were more frequently smaller in T-class (T1–T2) and 
had a high propensity to localize in tonsils, whereas EBER-
negative tumors were more often advanced (T3–T4) and 
had a less imbalanced distribution in oropharyngeal sub-
localizations. None of the polyomaviruses had an impact 
on any of the clinicopathological factors. The differences 
in clinicopathological factors between different viruses are 
shown in Table 2.
The impact of different viruses on prognosis
The median follow-up time of the patients was 46 months 
(range 0–66 months). Patients with HPV-positive tumors 
had a significantly more favorable OS (p = 0.002) and DFS 
(p = 0.001) compared with HPV-negative tumors. EBV, 
EBER, JCV, or SV40 did not have a significant impact 
on OS (Fig. 2) or DFS (Fig. 3) when compared indepen-
dently. As HPV positivity was significantly related to EBER 
positivity, we compared the differences in patient survival 
between patients with different combinations of HPV and 
EBER tumors. OS and DFS did not differ significantly 
between patients carrying HPV and EBER-negative OPSCC 
and HPV-positive OPSCC regardless of EBER expression. 
Patients with HPV-negative but EBER-positive OPSCC 
had significantly poorer OS and DFS when compared with 
patients carrying HPV-positive OPSCC regardless of EBER 
expression (Figs. 2 and 3).
Discussion
This study provides new evidence on the presence of EBV 
and the polyomaviruses JCV, BKV, and SV40 in OPSCC. 
Our results also support the paradigm of HPV as the pre-
dominant virus in OPSCC. Although several viruses have 
been detected in HNSCC, the most important viruses are 
HPV in OPSCC and EBV in NPC [1–3, 5, 14, 26]. The etio-
logic role of HPV and EBV in the pathogenesis and prog-
nosis of OPSCC and NPC, respectively, is well-established 
[1, 2, 19, 21]. However, there are only limited data on other 
oncoviruses except HPV in the etiopathogenesis of OPSCC. 
To our knowledge, this is the first study focusing not only on 
the detection but also the prognostic role of other oncogenic 
viruses in OPSCC.
Our analysis revealed EBER expression in approximately 
one-third of OPSCC samples. Instead of being present in 
Fig. 1  a Positive EBER tissue expression in the surrounding inflam-
matory cells of an OPSCC sample (white arrows). b Negative EBER 
tissue expression of an OPSCC sample. c Positive p16 tissue expres-
sion of an OPSCC sample. d Negative p16 tissue expression of an 
OPSCC sample. e Hematoxylin and eosin staining of a HPV-positive 
OPSCC sample. f Hematoxylin and eosin staining of a HPV-negative 
OPSCC sample. Scale bar length 50  μm. Magnifications are × 150 
(a–d) and × 200 (e–f)
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tumor cells, EBER was expressed only in the stromal inflam-
matory cells closest to the tumor invasive front. Interest-
ingly, EBER expression correlated significantly with tumor 
HPV positivity. The positive EBER expression in different 
HNSCCs (including a few OPSCC samples) has been pre-
sented recently [4]. Although the presence of HPV/EBV 
coinfection in OPSCC has been reported previously [39, 40], 
we are the first to show a significant correlation between 
EBER positivity and HPV positivity in OPSCC in a rela-
tively large patient cohort. Recently, it has been reported 
that EBERs, which are the sign of latent EBV infection, 
are secreted from EBV-infected cells and are recognized 
by toll-like receptor 3. This recognition leads to the induc-
tion of type I IFNs and inflammatory cytokines and sub-
sequent immune activation [41, 42]. Thus, lymphocytes 
carrying latent EBV infection might aid immune activation 
as the EBER positivity in inflammatory cells can be inter-
preted as cleared EBV infection of tumor cells [4]. It has 
been suggested that the presence of EBV may increase the 
invasiveness of HPV-positive OPSCC tumors [39]. On the 
other hand, the presence of EBV is more related to epithe-
lial dysplasia and precancerous tissue than to a higher stage 
of a malignant disease [43]. In our study, EBER positivity 
was related to lower T class and EBV DNA positivity to the 
lower stage. This may be due to the fact that the majority 
of EBER-positive and EBV DNA-positive tumors were also 
HPV positive; HPV-positive tumors are generally present 
with lower T class and are classified at a lower stage (I-II) 
according to the newest TNM classification [18, 29]. Neither 
EBER nor EBV DNA positivity had an impact on progno-
sis when compared with patients with EBER-negative and 
EBV-negative tumors, respectively. However, it appeared 
that among the HPV-negative subgroup, those with EBER-
positive tumors had significantly poorer outcomes than 
patients with HPV-positive tumors. To our knowledge, this 
has not been reported previously for OPSCC. In NPC, EBV 
has a clear prognostic role and EBV-specific immunotherapy 
has recently showed promising results [1, 44, 45]. Accord-
ing to our results, EBV may have also prognostic impact on 
OPSCC. Therefore, its prognostic significance in OPSCC 
should be studied more profoundly in the future. Regarding 
EBV and HPV synergy, it has been speculated that HPV 
may inhibit EBV lytic replication, facilitating the establish-
ment of EBV latency [46]. EBER positivity is associated 
with poorer survival in HNSCC [4] even though its favora-
ble impact on the prognosis of NPC is well-established [1]. 
Our analysis suggests that EBV may act as a cofactor in 
HPV-associated OPSCC, as previously suggested [39, 46]. 
In addition, EBV-specific immunotherapy has showed prom-
ising results in NPC [44, 45]. According to our results, EBV 
may have a prognostic impact on OPSCC and should be 
taken into account in future study designs and treatment 
approaches.
Different polyomaviruses, including JCV, BKV, and 
SV40 have been proposed to act as cofactors in oncogenic 
transformation and tumor progression in different cancers [3, 
7]. Here we detected BKV DNA in 46 tumors (29%). This 
amount is higher than previously reported in HNSCC, par-
ticularly in OPSCC [3, 24]. JCV DNA was present in 13.9% 
of our OPSCC samples. JCV has also been detected in phar-
yngeal carcinoma (site not specified) with higher copy num-
bers than found in corresponding normal tissue, although 
the numbers analyzed are still limited [3, 47]. The presence 
of BKV and JCV DNA in OPSCC was expected as these 
viruses are known to infect B lymphocytes, which are also 
abundantly present in the oropharynx [38, 48]. We found 
that coinfections as part of HPV-positive tumors were addi-
tionally positive for BKV DNA and JCV DNA. However, 
in our series positivity for neither BKV nor JCV yielded 
any statistically significant differences in clinicopathologi-
cal characteristics when compared with BKV-negative and 
JCV-negative patients, respectively. Only one tumor sample 
was positive for SV40DNA. SV40 DNA has been detected 
previously in different HNSCCs, such as lip and larynx can-
cer, but not in OPSCC [3]. Our results thus indicate that the 
role of polyomaviruses in OPSCC seems to be insignificant.
The relationship between p16 immunopositivity and HPV 
DNA presence in OPSCC is well-established [49]. The most 
recent TNM classifications stratify OPSCC into two disease 
entities according to p16 status [29, 30], despite its limita-
tions as a standalone surrogate marker for HPV involvement 
in OPSCC [32]. In addition to HPV, other oncoviruses that 
interact with the retinoblastoma (pRb) pathway have been 
suggested to cause p16 overexpression in OPSCC [33]. 
However, there may be other mechanisms, such as point 
mutations and gene deletions that lead to inactivation of pRb 
and overexpression of the p16 protein [11]. As the other 
HPV-independent factors that potentially lead to p16 overex-
pression are poorly understood, our objective was to evaluate 
the association between p16 immunopositivity and the pres-
ence of the viruses studied here. We found EBV, JCV, and 
BKV DNA in a subgroup of p16-positive but HPV-negative 
tumors. Thus, p16 may be overexpressed due to other viruses 
independently of HPV. Previously, it has been shown that the 
T-antigen of JCV and BKV interacts with pRb and may lead 
to inactivation of pRb [50]. EBV infection has been found 
to decrease expression of pRb [51, 52]. These findings may 
partly explain the elevated p16 expression in JCV, BKV, and 
EBV DNA-positive tumors. However, the majority of the 
tumors that were solely EBV, JCV, or BKV positive were 
p16 negative.
As expected, we also confirmed that over half (59.5%) of 
the OPSCCs associated with HPV, consistent with previous 
observations in Finland [15]. Our analysis also confirmed the 
close association between p16 immunopositivity and HPV 
presence in OPSCC tumors. Consistent with the previous 
1624 Cancer Immunology, Immunotherapy (2020) 69:1615–1626
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reports, patients with HPV-positive OPSCC had significant 
differences in patient- and tumor-related factors compared 
with HPV-negative OPSCC patients [2, 14, 53, 54]. Patients 
with HPV-positive OPSCC had significantly more favorable 
OS and DFS compared with their HPV-negative counter-
parts, as established earlier [2, 14, 15, 19].
This study has some limitations. Alcohol use was not 
known for every patient and EBER ISH was not avail-
able for all patients due to the absence of tumor samples 
or tumor tissue of insufficient size. The strengths of the 
present study are the relatively large patient cohort with 
long follow-up time. In addition, p16 status and viral DNA 
status could be determined for each tumor sample, thus 
allowing comprehensive analyses.
Conclusions
We showed that polyomaviruses are detectable in OPSCC 
but seem to have no association with clinicopathological 
features or prognosis. EBER RNA expression was not found 
in tumor cells but rather in the stromal lymphocytes adja-
cent to the invasive front. EBER expression was associated 
with HPV positivity. However, EBER expression in HPV-
negative OPSCC had tendency to associate with poorer sur-
vival when compared with patients with HPV-negative and 
EBER-negative OPSCC, which to our knowledge is a novel 
observation. HPV was the only virus that had significant 
impact on prognosis and correlated significantly with p16 
status. HPV presence in our series divided OPSCC into two 
disease entities according to clinicopathological factors. 
However, EBER analysis might identify a new subgroup of 
patients with OPSCC that is not related to HPV.
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